Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (5145)	8/24/1998 9:17:00 PM
From: B.REVERE	Read Replies (2) \| Respond to of 9523

[Death count at 69]-- Can someone elaborate on this? "At least 66 of the patients who died were men, the agency said. The average age of the patients in 55 reports which included that information was 64, the FDA said. The ages of patients who died ranged from 29 to 87, the agency said. " Are we to assume that the other three were women or was the FDA unable to determine the sex? Maybe Mulder and Scully need to take a look and give their unbiased written report. After all, Pfe will have to redo their label when women get approved for this. If our alien bretheren have started using the blues, pfe might as well include that group in their advisory, as well. All kidding aside, this death report was printed after the bell as far as I can tell. Unless the street had the info already, we could see another drop tomorrow. Maybe pfe is waiting for the general release of this report first and then prints the EU approval later in the afternoon. Either the drop was related to the no-news release on the EU approval or the death report once again scared the money managers to "shoot first, ask questions later." Still long pfe, BR